Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023051 | 0.94 | MAOA (0.45) | — | |
| SCHEMBL12487684 | 0.90 | ALDH1A1 (0.48) | ALDH1A1HPGDGABRA1GABRB2LMNA | |
| SCHEMBL11024908 | 0.83 | KDM4A (0.48) | ALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL14059371 | 0.83 | ALDH1A1 (0.43) | ALDH1A1HPGDGABRA1GABRB2LMNA | |
| SCHEMBL28501492 | 0.77 | MEN1 (0.58) | ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL2401264 | 0.73 | ADRA2C (0.42) | KDM4E | |
| SCHEMBL12487467 | 0.72 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNASMN1; SMN2KDM4E | |
| SCHEMBL10722469 | 0.71 | HPGD (0.69) | ALDH1A1HPGDGABRA1GABRB2LMNA | |
| SCHEMBL11020367 | 0.71 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10458612 | 0.71 | KDM4E (0.55) | ALDH1A1HPGDLMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8709129-B2 | Compounds useful as ligands of actinides, their synthesis and their uses | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-04-29 | — | — | US | claimed |
| EP-2456766-B1 | COMPOUNDS SUITABLE FOR USE AS ACTINIDE LIGANDS, SYNTHESIS AND USES THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2013-11-06 | — | — | EP | claimed |
| US-20120186396-A1 | COMPOUNDS USEFUL AS LIGANDS OF ACTINIDES, THEIR SYNTHESIS AND THEIR USES | UNIVERSITE DE NANTES (FR) | 2012-07-26 | — | — | US | claimed |
| US-8709129-B2 | Compounds useful as ligands of actinides, their synthesis and their uses | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2456766-B1 | COMPOUNDS SUITABLE FOR USE AS ACTINIDE LIGANDS, SYNTHESIS AND USES THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-20120186396-A1 | COMPOUNDS USEFUL AS LIGANDS OF ACTINIDES, THEIR SYNTHESIS AND THEIR USES | UNIVERSITE DE NANTES (FR) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120186396-A1 | COMPOUNDS USEFUL AS LIGANDS OF ACTINIDES, THEIR SYNTHESIS AND THEIR USES | AHR, ARNT, HRH3 | ALDH1A1 2567/4885HPGD 872/4885GABRA1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.